SciClone Pharmaceuticals, Inc. SCLN
Set alert
At close · Jun 28
- Open
- 11.15
- Prev close
- 11.15
- Mkt cap
- 581.94M
- Vol
- 2.22M
- Avg vol
- 443.30K
- EPS
- 0.811
- P/E
- 13.75
- Div yield
- 0.00%
More statistics
- Low
- 11.15
- High
- 11.20
- Forward P/E
- 10.42
- Beta
- 1.25
- Short ratio
- 2.34
- Inst. own
- 79.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 30, 2019
- 50-d avg
- 11.14
- 200-d avg
- 10.66
- 1y target
- 14.00
Key statistics
- Market cap
- 581.94M
- Enterprise value
- 422.00M
- Trailing P/E
- 13.75
- Forward P/E
- 10.42
- PEG ratio
- 0.84
- Price / sales
- 3.38
- Price / book
- 2.33
- EPS (TTM)
- 0.811
- Beta
- 1.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 25.18%
- Revenue (TTM)
- 172.02M
- Revenue growth
- 14.20%
- Free cash flow
- 17.96M
- Total cash
- 157.33M
- Total debt
- 0
- Return on equity
- 19.56%
- Shares outstanding
- 52.19M
- Short % of float
- 2.74%
- 50-day average
- 11.14
- 200-day average
- 10.66
Analyst view
Consensus: hold
Next earnings
Nov 30, 2019
Expected Nov 30, 2019. Consensus EPS estimate 0.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 30, 2019 | Mar 1, 2013 | 0.00 | — | — | — |
| Nov 8, 2017 | Sep 1, 2017 | 0.00 | — | — | — |
| Aug 9, 2017 | Jun 1, 2017 | 0.00 | — | — | — |
| May 10, 2017 | Mar 1, 2017 | 0.00 | — | — | — |
| Mar 6, 2017 | Dec 1, 2016 | 0.00 | — | — | — |
| Nov 9, 2016 | Sep 1, 2016 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 28, 2016 | Maxim Group | init | — | Buy |
| Jun 28, 2015 | MLV & Co. | init | — | Buy |
| Nov 13, 2014 | BWS Financial | down | — | Hold |
| Jul 15, 2013 | Aegis Capital | up | — | Buy |
| Feb 24, 2013 | Aegis Capital | down | — | Hold |
| Sep 17, 2012 | BWS Financial | up | — | Buy |
About SciClone Pharmaceuticals, Inc.
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the Peoples Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhancer. In addition, the company focuses on developing ZADAXIN for the treatment of sepsis. SciClone Pharmaceuticals, Inc. markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets and distributes products, such as DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, Angiomax, and Cleviprex. The company has a strategic partnership with The Medicines Company to promote Angiomax (bivalirudin) and Cleviprex (clevidipine). SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Other
- Country
- United States
- Website
- sciclone.com
News
Your note
Sign in to keep a note on SCLN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLY BRIDGE LB HEALTHCARE MASTER FUND LTD | Other | Ownership Statement | Feb 21, 2016 | 678,077 |
| BLOBEL FRIEDHELM | Officer | Disposition (Non Open Market) | Oct 12, 2017 | 0 |
| CHANG NANCY T | Director | Disposition (Non Open Market) | Oct 12, 2017 | 0 |
| CHERN CAREY | Officer | Disposition (Non Open Market) | Oct 12, 2017 | 0 |
| CHEUNG WILSON WAI-SHUN | Officer | Disposition (Non Open Market) | Oct 12, 2017 | 0 |
| DRAGON ALPHA LP | Other | Ownership Statement | Feb 21, 2016 | 8,888 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.04% | 7,329,390 | 79.89M | Jun 29, 2017 |
| Vanguard Group, Inc. (The) | 5.67% | 2,957,371 | 32.24M | Jun 29, 2017 |
| Dimensional Fund Advisors LP | 5.53% | 2,886,532 | 31.46M | Jun 29, 2017 |
| Renaissance Technologies, LLC | 4.87% | 2,540,200 | 27.69M | Jun 29, 2017 |
| GLG Partners LP | 3.04% | 1,588,897 | 17.32M | Jun 29, 2017 |
| State Street Corporation | 2.89% | 1,508,053 | 16.44M | Jun 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 4.25% | 2,219,274 | 24.19M | Jun 29, 2017 |
| Vanguard Total Stock Market Index Fund | 2.07% | 1,078,470 | 10.57M | Mar 30, 2017 |
| iShares Russell 2000 ETF | 1.97% | 1,026,249 | 11.19M | Jun 29, 2017 |
| iShares U.S. Pharmaceuticals ETF | 1.25% | 651,577 | 7.10M | Jun 29, 2017 |
| Vanguard Extended Market Index Fund | 1.23% | 641,818 | 6.29M | Mar 30, 2017 |
| iShares S&P Small Cap 600 Growth Index ETF | 1.21% | 630,554 | 6.87M | Jun 29, 2017 |